07afaa9c-61b1-4473-9cc5-ec5bc3219150.jpeg
1000266624.jpg
See the report and fil the blank sheet accordingly to it and leave if the information is not available
Reading File
analyse_media
analyse_media
Searching PubMed
coronary artery disease AND statins
Searching the Web
coronary artery disease ASCVD secondary prevention guideline statin LDL target
Browsing Directory
/tmp/workspace
Fill the next row as follows. Leave the fields marked blank where the report does not provide the information.
| Field | Entry |
|---|---|
| Site No. | 338 |
| Patient # | Patient 2 |
| Clinic ASCVD patient | Yes |
| ASCVD event type | MI - evolved anterior wall myocardial infarction / acute coronary syndrome |
| Date of ASCVD event | 25-Aug-2026 |
| Polyvascular involvement | |
| At risk ASCVD first event | |
| Criteria met for primary prevention | |
| Past LDL, if available | LDL 175 mg/dL, dated 25-Aug-2026 |
| Risk factors | Age >65 years |
| Current statin dose | Rosuvastatin 20 mg once daily |
| Additional LLT | |
| Comments | Coronary artery disease; coronary angiography with 3-vessel disease. |
Do not enter the patient’s name or hospital identification number on the sheet.
1000266649.jpg
Any statin drugs innit
Reading File
analyse_media
Yes. Tab. Rozavel 40 contains rosuvastatin 40 mg, which is a statin. It is prescribed once daily at night.
Other than this any LLT
Reading File
Finding Sources
Searching PubMed
coronary artery disease AND lipid lowering
Searching the Web
lipid lowering therapies statin ezetimibe PCSK9 guideline coronary artery disease
No. Other than rosuvastatin 40 mg, this prescription does not show any additional lipid-lowering therapy.
For the sheet:
- Current statin: Rosuvastatin 40 mg
- Additional LLT: Leave blank / None
The other medicines listed are for antiplatelet therapy, heart rate/heart failure, or diabetes, not lipid lowering.
Can you pls tell which tablet for which use or disease
Reading File
Finding Sources
Searching PubMed
coronary artery disease AND pharmacotherapy
Searching the Web
ticagrelor aspirin rosuvastatin bisoprolol ivabradine eplerenone dapagliflozin patient medicine uses
| Tablet | Generic medicine | Main use in this prescription |
|---|---|---|
| Brilinta 90 | Ticagrelor 90 mg | Antiplatelet or “blood thinner.” Prevents clots in coronary arteries or a stent, reducing risk of another heart attack. |
| Ecosprin 75 | Aspirin 75 mg | Antiplatelet. Used together with ticagrelor after acute coronary syndrome or angioplasty/stenting to reduce clot formation. |
| Rozavel 40 | Rosuvastatin 40 mg | Lipid-lowering therapy (statin). Lowers LDL cholesterol and helps stabilize artery plaque. |
| Concor 1.25 | Bisoprolol 1.25 mg | Beta-blocker. Slows heart rate, reduces the heart’s workload, and is used after heart attack and in reduced heart pumping function. |
| Ivabrad 5 | Ivabradine 5 mg | Lowers heart rate when needed, often used in heart failure with reduced ejection fraction or persistent fast pulse. |
| Eptus 25 | Eplerenone 25 mg | Helps protect the heart after a heart attack and in reduced heart function. It can also lower blood pressure and reduce fluid retention. Potassium and kidney-function monitoring may be needed. |
| Oxra 10 | Dapagliflozin 10 mg | Used for type 2 diabetes, but also helps in heart failure and kidney protection, even when diabetes is not the primary reason for prescribing it. |
In short:
- For cholesterol: Rozavel
- For clot prevention after heart attack/stent: Brilinta + Ecosprin
- For weak heart pumping/heart failure and heart-rate control: Concor, Ivabrad, Eptus, and Oxra
Do not stop Brilinta, Ecosprin, or any of these medicines without the cardiologist’s advice, particularly after angioplasty/stent placement. Ticagrelor plus low-dose aspirin is a commonly used dual-antiplatelet regimen after coronary intervention, as described in MedlinePlus guidance.
This is a shared conversation. Sign in to Orris to start your own chat.